Stent-Retriever Thrombectomy: Impact on the Future of Interventional Stroke Treatment by Mordasini, P. et al.
1 3
Review aRticle
Received: 13 December 2013 / Accepted: 12 February 2014 / Published online: 22 February 2014
© Springer-Verlag Berlin Heidelberg 2014
Stent-Retriever Thrombectomy: Impact on the Future  
of Interventional Stroke Treatment
P. Mordasini · C. Zubler · K. Wha-Vei Hsieh ·  
P. K. Chan · J. Gralla
Clin Neuroradiol (2014) 24:17–22
DOI 10.1007/s00062-014-0299-1
The prevalence of acute ischemic stroke is age depen-
dent and increases significantly above the age of 65 years 
[2]. Taking into account the expected demographic develop-
ment in the aging population of industrialized nations, the 
total number of strokes is likely to increase within the next 
decades. Based on the demographic data from Germany, 
the number of inhabitants above the age of 65 years, and 
therefore within the age more prone for ischemic cerebro-
vascular events, rose from approximately 7 million (10 % 
of the overall population) in 1950 to 17 million (23 %) in 
2013 and is expected to rise to approximately 23 million 
(33 %) in 2050 (Fig. 1). Optimized and effective treatment 
approaches for this devastating disease are mandatory in the 
future. Intravenously administered tissue plasminogen acti-
vator (IV tPA) has proven to be effective in the treatment of 
stroke patients when applied within a 4.5-h time window.
However, the success of recanalization depends on the 
occlusion site; proximal occlusions of large vessels such as 
the internal carotid artery (ICA) have a poor recanalization 
rate after either IV tPA or IAT [3, 4]. Furthermore, the time 
window for treatment and the recanalization rate is limited 
[3–5], and the application of thrombolytic drugs increases 
the risk of symptomatic intracranial hemorrhage (sICH) [6]. 
Recent studies have examined whether endovascular recan-
alization techniques can accelerate the process of recana-
lization, increase the recanalization rate, and even expand 
the window of opportunity. However, endovascular stroke 
treatment has failed to show superiority to sole intravenous 
thrombolysis in the recently published three randomized 
controlled trials (RCTs): Interventional Management of 
Stroke (IMS)-III, SYNTHESIS Expansion, and MR RES-
CUE [7–9].
This review describes the recent evolution of endovascu-
lar stroke treatment and summarizes the clinical results of 
stent-retriever (SR) thrombectomy. On the basis of the cur-
Abstract Endovascular treatment for acute ischemic stroke 
has evolved in the past years. The current development of 
stent-retriever thrombectomy is a landmark in the clinical 
treatment and study results of acute ischemic stroke. This 
review summarizes the recent study results, elucidates the 
shortcomings of endovascular stroke treatment, and takes 
the opportunity for an outlook on the role of stroke inter-
ventions in the future.
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Introduction
Acute ischemic stroke is one of the major causes of morbidity 
and mortality in Western countries. The neurological outcome 
depends on the length of time between onset of symptoms 
and treatment, and on whether recanalization of the occluded 
vessel can be achieved. The chance of an independent life 
after stroke increases 4.4 times for patients with successful 
recanalization compared with patients without recanalization. 
At the same time, mortality rate decreases fourfold [1].
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rent data on stroke treatment, the authors advocate the role 
of the endovascular approaches in the future.
Thrombectomy Techniques
The various techniques and approaches for mechanical throm-
bectomy (MT) have evolved over time and can be divided 
into three categories: proximal aspiration, distal thrombec-
tomy and in-thrombus approaches such as placement of self-
expandable stents, and SR thrombectomy (Fig. 2). All MT 
devices are delivered by endovascular access to the occlu-
sion site. The various devices can be divided into three major 
groups according to where they apply force on the thrombus.
Proximal devices apply force to the proximal base of 
the thrombus; this group includes various aspiration cath-
eters and systems. Distal devices approach the thrombus 
proximally, but then are advanced by a microcatheter to 
pass the thrombus and to be unsheathed behind it, where 
force is applied to the distal base of the thrombus; this 
group includes brush-, basket-, or coil-like devices. Proxi-
mal and distal approaches can be considered as first-gen-
eration approaches. The second-generation devices include 
stent-like devices that are placed across the occlusion side, 
deployed within the thrombus and then retrieved; this group 
includes various self-expandable stent-retrievers (SR).
Studies on First-Generation Devices
First-generation devices have been studied extensively 
in single-arm studies. The Penumbra system (Penumbra, 
Alameda, CA, USA) is a refinement of the proximal throm-
bectomy technique and applies continuous aspiration in 
conjunction with mechanical fragmentation.
The Penumbra Pivotal Stroke Trial [10] prospectively 
examined the results in 125 stroke patients (mean National 
Institute of Health Stroke Scale (NIHSS) score: 18) within a 
window of 8 h after onset of symptoms. Recanalization of the 
target vessel was achieved in 81.6 % of patients. Despite the 
convincing recanalization rate, clinical outcome was poor; 
favorable clinical outcome was achieved in only 25 % of 
all patients and in 29 % of those with successful recanaliza-
tion. The rate of sICH was 11.2 %, and overall mortality was 
32.8 %. Serious adverse events occurred in 3.2 % of cases. 
The discrepancy between high recanalization rates and poor 
Fig. 2 a Proximal thrombectomy by aspiration. A large-diameter 
catheter is advanced to the proximal surface of the thrombus. Under 
continuous aspiration, the device is then retrieved, mobilizing the 
thrombus from the cranial vessels. b Distal thrombectomy. Passing the 
occlusion site and developing a cage-, net-, or coil-like device distally 
to the thrombus, the device is retrieved together with the thrombus. 
c Stent-retriever thrombectomy. After placement of the self-expand-
able device and thrombus compression, generating a temporal bypass 
effect, the device is retrieved together with the thrombus from the in-
tracranial vasculature
 
Fig. 1 Demographic development of the German population from 1950 to 2013 and estimated development until 2050. The number of people 
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promising new treatment option for acute ischemic stroke. 
Numerous variants of this device type are currently under 
development or in first clinical trials (e.g., Solitaire/Covi-
dien, TREVO/Concentric Medical, ERIC/MicroVention, 3D 
Separator/Penumbra, Preset/Phenox etc.).
Castano et al. [14] reported in an initial study in 2010 
on their experience in 20 acute stroke patients within an 
8-h time window. Successful recanalization was achieved 
in 90 % of cases with a mean procedural time of 50 min. 
A favorable clinical outcome was attained in 45 %, and 
sICH rate was 10 %. These results have been reproduced 
by various small case series and retrospective studies using 
SRs, which have shown similar successful recanalization 
rates (85–91 %) and fast procedural times (40–55 min) with 
comparable rates of favorable clinical outcome (42–55 %) 
[15–18].
The largest prospective study on SR thrombectomy was 
the Solitaire FR Thrombectomy for Acute Revasculariza-
tion (STAR) trial [19]. This prospective, international, 
single-arm study enrolled 202 consecutive patients (mean 
age: 72 years, mean baseline NIHSS score: 17) with ante-
rior circulation occlusion treated within an 8-h time win-
dow. For this study, all patients were selected on the basis 
of proximal vessel occlusion in cross-sectional imaging; 
furthermore, the use of a balloon guide catheter and flow 
reversal during thrombectomy was mandatory. The pri-
mary outcome, recanalization of Thrombolysis in Cerebral 
Infarction (TICI) ≥ 2b, was core laboratory controlled and 
achieved in 79.2 % of cases, resulting in a favorable clini-
cal outcome modified Ranking Scale (mRS) 0–2 in 57.9 %. 
Mean procedural time from placement of balloon guide 
catheter to recanalization was 29 min. Mortality was 6.9 %, 
sICH occurred in 1.5 %.
Unlike previous studies with first-generation devices, 
studies of SR thrombectomy revealed high recanalization 
rates, fast procedural times, and low rates of sICH, which 
ultimately correlate with the high rates of favorable clinical 
outcome (Table 1).
Comparison of First- and Second-Generation Devices
The Solitaire FR with the Intention for Thrombectomy 
(SWIFT) trial and the TREVO II trial were randomized tri-
als comparing the efficacy and safety of second-generation 
devices (Solitaire FR and TREVO) with that of a first-gen-
eration device, the Merci device. Both trials illustrated the 
inferiority of the first-generation devices compared with SRs.
The SWIFT trial [20] randomized 58 patients to the Soli-
taire group and 55 patients to the Merci group. The primary 
efficacy outcome, Thrombolysis in Myocardial Infarction 
(TIMI) 2–3 without sICH, was achieved more often in the 
Solitaire group (61 %) than in the Merci group (24 %). Fur-
clinical outcome has been discussed intensively. A possible 
explanation is due to the grading system of TIMI used in the 
study. A full recanalization could be achieved independent of 
reperfusion of the brain, an aspect which led to the applica-
tion of the TICI grading in future studies thereafter.
The initial Mechanical Embolus Removal in Cerebral 
Ischemia (MERCI) trial evaluated the safety and efficacy 
of the Merci system in the setting of acute stroke within 8 h 
of onset in 151 patients (mean NIHSS score: 20) who were 
ineligible for intra-arterial thrombolysis (IAT) [11]. The trial 
included patients with anterior circulation (90 %) and pos-
terior circulation (10 %) stroke. Successful recanalization 
was achieved in 46 % of the treated patients, significantly 
higher compared with the subgroup, with a spontaneous 
recanalization rate of 18 % in the Prolyse in Acute Cerebral 
Thromboembolism (PROACT) II trial [12]. Favorable clini-
cal outcome was achieved in 27.7 % of patients. The mean 
procedure duration was 2.1 h; clinically significant proce-
dural complications occurred in 7.1 % of patients, and the 
sICH rate was 7.8 %.
The Multi-MERCI trial was an international, single-arm 
trial that investigated 164 patients (mean NIHSS score: 19) 
within an 8-h window after symptom onset [13]. The pri-
mary end point was target vessel recanalization. In contrast 
to the MERCI trial, prior treatment with IV tPA, IAT, or 
other mechanical techniques was allowed, and new gen-
erations of the Merci device were included. Successful 
recanalization was achieved in 57.3 % of cases using the 
retriever alone and 69.5 % in conjunction with other treat-
ment modalities. Favorable clinical outcome was achieved 
in 36 % of patients. Mean procedure duration was 1.6 h and, 
therefore, again remarkably long for a mechanical approach. 
Clinically significant procedural complications occurred in 
5.5 % of patients, and the sICH rate was 9.8 %.
The introduction of aspiration and distal devices has 
been a landmark of mechanical recanalization in stroke 
treatment, but the studies illustrated high recanalization 
rates in correlation to moderate or poor clinical results. 
However, due to novel developments in aspiration catheter 
technology, this technique might show improved results in 
the future. Due to their early Food and Drug Administration 
approval, both approaches have been assessed within the 
IMS-III trial [7].
Second-Generation Devices
The most recently introduced mechanical devices for acute 
stroke treatment are self-expandable, stent-like throm-
bectomy devices. Combining the advantages of tempo-
rary stenting with immediate flow restoration without the 
need for permanent implantation plus thrombectomy with 
definitive thrombus removal, stent-retrieval devices offer a 
20
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The Shortcoming of Endovascular Treatment
At the same time, the recent studies and trials revealed major 
shortcomings of current endovascular stroke treatment 
approaches, i.e., the missing standardization of the proce-
dures. Although many aspects of acute ischemic stroke are 
well investigated and the current endovascular approaches 
show high recanalization rates, impact of patient selection in 
the peri-procedural management during stroke interventions 
are poorly understood. In clinical practice as well as in stud-
ies, many crucial aspects are undefined or arbitrarily chosen.
The role of peri-procedural anticoagulation and plate-
let inhibition during stroke interventions is still unknown. 
Although increased rates of sICH in conjunction with dif-
ferent drugs have been shown by various stroke studies 
and reviews [24], no common agreement on their applica-
tion during stroke interventions is established; in fact, the 
reported protocols differ significantly. This is even more 
surprising taking into account that many patients are treated 
by thrombectomy because of pre-existing anticoagulation 
and contraindication for IV tPA. Furthermore, in case of 
stent recanalization of access vessels, the role and timing of 
antiplatelet medication becomes essential.
Various retrospective studies and subgroup analysis have 
reported different rates of favorable outcome in patients 
treated endovascularly depending on the anesthesia protocol 
[25, 26]. Most data illustrated a significantly worse outcome 
following general anesthesia (GA) compared with con-
scious sedation or treatment under local anesthesia of the 
groin only. However, these studies lack randomization and 
are biased by the fact that by trend, patients with more com-
plex occlusions (e.g., tandem occlusions) and those restless 
along with high NIHSS scores and presenting incompli-
ance are treated under GA. Nevertheless, various factors 
have been considered to contribute to worse outcome after 
GA. The intubation is time-consuming and causes a clini-
thermore, good 3-month neurological outcome (defined 
as mRS ≤ 2 or equal to the prestroke mRS if the prestroke 
mRS was > 2 or NIHSS score improvement of 10 points or 
more) was significantly more often achieved with the Soli-
taire than with Merci device (58 versus 33 %), while 90-day 
mortality was higher in the Merci group compared with the 
Solitaire group (17 versus 38 %).
The TREVO II trial [21] randomly assigned 88 patients 
to the TREVO Retriever group and 90 patients to Merci 
Retriever group. Recanalization rate (TICI 2–3) was signifi-
cantly higher in the TREVO group (86 %) compared with 
the Merci group (60 %). Incidence of the primary safety end 
point did not differ between groups.
The Current Study Situation
The most recent landmark in stroke research was the pub-
lication of three RCTs: IMS-III, SYNTHESIS Expansion, 
and MR RESCUE [7–9]. All trials compared the clinical 
outcome of stroke patients randomly assigned to IV tPA 
or MT in combination with IV tPA. All three trials were 
unable to show superiority of the endovascular approach 
compared with the sole application of IV tPA in differ-
ent study settings. The studies have been extensively dis-
cussed in the near past [22, 23]. Criticism on the study 
design mainly focuses on low recruitment rates of the 
studies, inclusion of patients without adequate imaging 
and proven proximal vessel occlusion, delayed treatment 
in the endovascular arm, and heterogeneity of the endovas-
cular techniques and protocols. Due to the late clearance 
of SR, in none of the studies were a substantial number 
of patients treated with second-generation devices. Taking 
into account the aforementioned RCT comparing first- and 
second-generation devices, an impact on the study results 
can be assumed.
Table 1 Core laboratory-controlled study results of mechanical thrombectomy using stent-retrievers
TREVO
2012










Device TREVO TREVO Solitaire Solitaire Solitaire
Number of patients 60 88 141 58 202
Age (mean) 65 (median) 67.4 66.3 67.1 68.4
Baseline NIHSS score (mean) 18 19 18 18 17
Posterior circulation (%) 8.3 8 11 1.7
Successful recanalization (%) 78.3 (TICI ≥ 2a) 86 (mTICI ≥ 2) 85 (TICI ≥ 2b) 75.9 (TICI ≥ 2b) 79.2 (TICI ≥ 2b)
mRS ≤ 2 at 3 months (%) 55.0 40 55 36.4 57.9
Mortality at 3 months (%) 20 33 20 17.2 6.9
sICH at 24 h (%) 5 7 4 1.7 1.5
TREVO study [27], TREVO II trial [21], Retrospective study on Solitaire [16], SWIFT trial [20], STAR study [19] 
SR stent-retriever, SWIFT Solitaire FR with the Intention for Thrombectomy, STAR Solitaire FR Thrombectomy for Acute Revascularization, 
sICH symptomatic intracranial hemorrhage, NIHSS National Institute of Stroke Scale, TICI Thrombolysis in Cerebral Infarction, mTICI 
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However, although we have a very sufficient tool for 
fast recanalization in our hands now, interventionists have 
failed to set up guidelines and standardized protocols for the 
intervention as well as the peri-procedural patient manage-
ment yet. Many of these might have a significant impact 
on patients’ outcome and might jeopardize patients’ recov-
ery despite successful recanalization. Attention and inves-
tigation are urgently required to standardize endovascular 
stroke treatment for the future.
Conflict of Interest We declare that none of the authors has a conflict 
of interest. J. Gralla was the Principal Investigator of the STAR study.
References
 1. Rha JH, Saver JL. The impact of recanalization on ischemic stroke 
outcome: a meta-analysis. Stroke. 2007;38(3):967–73.
 2. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: cur-
rent concepts, and estimates from the Framingham Study. Lancet 
Neurol. 2007;6(12):1106–14.
 3. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et 
al. Intravenous recombinant tissue plasminogen activator in acute 
carotid artery territory stroke. Neurology. 1992;42(5):976–82.
 4. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, 
Calleja S, et al. Site of arterial occlusion identified by transcra-
nial Doppler predicts the response to intravenous thrombolysis for 
stroke. Stroke. 2007;38(3):948–54.
 5. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Fer-
bert A, et al. Recombinant tissue plasminogen activator in acute 
thrombotic and embolic stroke. Ann Neurol. 1992;32(1):78–86.
 6. Brekenfeld C, Remonda L, Nedeltchev K, Arnold M, Mattle HP, 
Fischer U, et al. Symptomatic intracranial haemorrhage after intra-
arterial thrombolysis in acute ischaemic stroke: assessment of 294 
patients treated with urokinase. J Neurol Neurosurg Psychiatry. 
2007;78(3):280–5.
 7. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill 
MD, et al. Endovascular therapy after intravenous t-PA versus t-PA 
alone for stroke. N Engl J Med. 2013;368(10):893–903.
 8. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi 
R, et al. Endovascular treatment for acute ischemic stroke. N Engl 
J Med. 2013;368(10):904–13.
 9. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, 
et al. A trial of imaging selection and endovascular treatment for 
ischemic stroke. N Engl J Med. 2013;368(10):914–23.
10. The Penumbra Pivotal Stroke Trial Investigators. The penumbra 
pivotal stroke trial: safety and effectiveness of a new generation 
of mechanical devices for clot removal in intracranial large vessel 
occlusive disease. Stroke. 2009;40(8):2761–8.
11. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, 
et al. Safety and efficacy of mechanical embolectomy in acute isch-
emic stroke: results of the MERCI trial. Stroke. 2005;36(7):1432–8.
12. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, 
et al. Intra-arterial prourokinase for acute ischemic stroke. The 
PROACT II study: a randomized controlled trial. Prolyse in Acute 
Cerebral Thromboembolism. JAMA. 1999;282(21):2003–11.
13. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind 
DS, et al. Mechanical thrombectomy for acute ischemic stroke: 
final results of the Multi MERCI trial. Stroke. 2008;39(4):1205–12.
14. Castano C, Dorado L, Guerrero C, Millan M, Gomis M, Perez de 
la Ossa N, et al. Mechanical thrombectomy with the Solitaire AB 
device in large artery occlusions of the anterior circulation: a pilot 
study. Stroke. 2010;41(8):1836–40.
cally relevant time delay in comparison with patients treated 
without it. Furthermore, introduction of GA is often accom-
panied by a decreased systemic blood pressure, resulting in 
reduced collateral pial blood flow [25]. This reduction of 
collateral flow might cause infarct growth during interven-
tion until reperfusion is achieved.
Since the introduction of MT, studies illustrated a shift 
toward peri-procedural complications, some of them with 
possible impact on patients’ outcome (e.g., dissections, 
perforations, and thromboembolic events into previously 
unaffected vascular territories) [10, 11, 13, 19]. To date, no 
standardized reporting of peri-interventional complications 
has been established clinically or in study protocols. For 
second-generation SR thrombectomy, proximal flow rever-
sal has been advocated and reasonable; however, so far, its 
application is not mandatory.
An Outlook on Endovascular Stroke Treatment in the 
Future
Fast restoration of cerebral blood flow is the principal aim of 
stroke therapy, associated with better clinical outcome and 
reduced mortality rates after acute ischemic stroke. Second-
generation MT devices using SRs have been shown in sin-
gle-arm studies to achieve high recanalization rates and fast 
procedural times, which—unlike first-generation devices—
ultimately correlate with high rates of favorable clinical 
outcome. The superiority of second-generation devices has 
been illustrated in trials comparing first- and second-gener-
ation devices. Therefore, the recently published RCT on IV 
tPA versus MT do not reflect the current state of the art in 
endovascular stroke treatment, as SRs have not been applied 
in a substantial number of patients in the trials. However, to 
date, no RCT has proven the superiority of MT in compari-
son with sole IV tPA.
From the authors’ point of view, the current data on endo-
vascular stroke treatment using SRs advocate this approach 
for standard treatment of acute ischemic stroke in the future. 
The mechanical approaches have undoubtedly expanded the 
time window for stroke treatment beyond 4.5 h and broad-
ened the treatment for patients in whom IV tPA or IAT failed 
or is contraindicated. Considering the poor recanalization 
rate and clinical outcome of patients suffering from proxi-
mal vessel occlusions and large thrombus burden (e.g., tan-
dem occlusions and ICA termination), SR thrombectomy is 
likely to become standard treatment also within the 4.5-h 
time window. RCTs are necessary to confirm this role in 
the future and to set the protocols of accompanying IV tPA 
or bridging therapy. The currently ongoing and upcoming 
trials (e.g., SWIFT Prime, THERAPY, PISTE, THRACE, 
REVASCAT, THRILL) will elucidate this role and are likely 
to be positive for MT.
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